{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:16:14Z","timestamp":1777097774770,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Heptares Therapeutics Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40268-021-00352-5","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T17:03:09Z","timestamp":1624467789000},"page":"295-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects"],"prefix":"10.1007","volume":"21","clinical-trial-number":[{"clinical-trial-number":"nl5915","registry":"10.18810\/dutch-trial-register"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-2354","authenticated-orcid":false,"given":"Charlotte","family":"Bakker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"van der Aart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Labots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Liptrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Klaassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Tasker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert Jan","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"issue":"4","key":"352_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","volume":"88","author":"CR Overk","year":"2014","unstructured":"Overk CR, Masliah E. Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy body disease. Biochem Pharmacol. 2014;88(4):508\u201316. https:\/\/doi.org\/10.1016\/j.bcp.2014.01.015.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"352_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380. https:\/\/doi.org\/10.1002\/ana.410300410.","journal-title":"Ann Neurol"},{"issue":"2","key":"352_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1471-4159.1995.64020749.x","volume":"64","author":"LM Bierer","year":"1995","unstructured":"Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, et al. Neurochemical correlates of dementia severity in Alzheimer\u2019s disease: relative importance of the cholinergic deficits. J Neurochem. 1995;64(2):749\u201360. https:\/\/doi.org\/10.1046\/j.1471-4159.1995.64020749.x.","journal-title":"J Neurochem"},{"issue":"2","key":"352_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/jad-132690","volume":"41","author":"CC Tan","year":"2014","unstructured":"Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615\u201331. https:\/\/doi.org\/10.3233\/jad-132690.","journal-title":"J Alzheimers Dis"},{"key":"352_CR5","unstructured":"Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ Can Med Assoc J (J Assoc Med Can) 2003;169(6):557\u201364."},{"issue":"4","key":"352_CR6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1046\/j.1471-4159.1995.64041888.x","volume":"64","author":"DD Flynn","year":"1995","unstructured":"Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer\u2019s disease. J Neurochem. 1995;64(4):1888\u201391.","journal-title":"J Neurochem"},{"issue":"24","key":"352_CR7","doi-asserted-by":"publisher","first-page":"13541","DOI":"10.1073\/pnas.93.24.13541","volume":"93","author":"AI Levey","year":"1996","unstructured":"Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA. 1996;93(24):13541\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4703","key":"352_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1126\/science.3992249","volume":"228","author":"DC Mash","year":"1985","unstructured":"Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer\u2019s disease and experimental cholinergic denervation. Science. 1985;228(4703):1115\u20137.","journal-title":"Science"},{"issue":"4","key":"352_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","volume":"54","author":"NC Bodick","year":"1997","unstructured":"Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465\u201373.","journal-title":"Arch Neurol"},{"issue":"4","key":"352_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1017\/s1461145712000752","volume":"16","author":"PJ Nathan","year":"2013","unstructured":"Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013;16(4):721\u201331. https:\/\/doi.org\/10.1017\/s1461145712000752.","journal-title":"Int J Neuropsychopharmacol"},{"key":"352_CR11","unstructured":"Congreve M, Brown AJH, J C. Identification of novel Muscarinic M1 agonist HTL0018318 using structure based drug design. J Am Chem Soc. 2020. (in preparation)."},{"issue":"1","key":"352_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13195-021-00816-5","volume":"13","author":"C Bakker","year":"2021","unstructured":"Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Doll RJ, et al. Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M(1) receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study. Alzheimers Res Ther. 2021;13(1):87. https:\/\/doi.org\/10.1186\/s13195-021-00816-5.","journal-title":"Alzheimers Res Ther."},{"key":"352_CR13","unstructured":"fachinformation.srz.de. Donepezil\u2014summary of product characteristics. http:\/\/fachinformation.srz.de\/lp\/aliudpharma\/donepezilal5mg10mgfilmtabletten. Accessed 05 May 2016."},{"key":"352_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14710","author":"C Bakker","year":"2020","unstructured":"Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, et al. First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M(1) -receptor partial agonist for the treatment of dementias. Br J Clin Pharmacol. 2020. https:\/\/doi.org\/10.1111\/bcp.14710.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"352_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A Bond","year":"1974","unstructured":"Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;47(3):211\u20138. https:\/\/doi.org\/10.1111\/j.2044-8341.1974.tb02285.x.","journal-title":"Br J Med Psychol"},{"issue":"2","key":"352_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00434408","volume":"71","author":"AC Parrott","year":"1980","unstructured":"Parrott AC, Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations\u2014a review. Psychopharmacology. 1980;71(2):173\u20139.","journal-title":"Psychopharmacology"},{"issue":"8","key":"352_CR17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-019-02673-6","volume":"75","author":"D Dai","year":"2019","unstructured":"Dai D, Yang H, Nabhan S, Liu H, Hickman D, Liu G, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019;75(8):1099\u2013108. https:\/\/doi.org\/10.1007\/s00228-019-02673-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"352_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40261-019-00775-8","volume":"39","author":"L Sun","year":"2019","unstructured":"Sun L, McDonnell D, Yu M, Kumar V, von Moltke L. A phase I open-label study to evaluate the effects of rifampin on the pharmacokinetics of olanzapine and samidorphan administered in combination in healthy human subjects. Clin Drug Investig. 2019;39(5):477\u201384. https:\/\/doi.org\/10.1007\/s40261-019-00775-8.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"352_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40261-019-00825-1","volume":"39","author":"Y Maekawa","year":"2019","unstructured":"Maekawa Y, Furuie H, Kato M, Myobatake Y, Kamiyama E, Watanabe A, et al. Effect of DS-8500a, a novel G protein-coupled receptor 119 agonist, on the pharmacokinetics of rosuvastatin and atorvastatin in healthy subjects. Clin Drug Investig. 2019;39(10):967\u201378. https:\/\/doi.org\/10.1007\/s40261-019-00825-1.","journal-title":"Clin Drug Investig"},{"issue":"7","key":"352_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","volume":"17","author":"FP Bymaster","year":"2003","unstructured":"Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci. 2003;17(7):1403\u201310.","journal-title":"Eur J Neurosci"},{"key":"352_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","volume":"4","author":"T Voss","year":"2018","unstructured":"Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia (New York, N Y). 2018;4:173\u201381. https:\/\/doi.org\/10.1016\/j.trci.2018.03.004.","journal-title":"Alzheimer's Dementia (New York, N Y)."},{"issue":"8","key":"352_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/j.1552-4604.1995.tb04123.x","volume":"35","author":"JJ Sramek","year":"1995","unstructured":"Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Hourani J, Dies F, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer\u2019s disease. J Clin Pharmacol. 1995;35(8):800\u20136.","journal-title":"J Clin Pharmacol"},{"key":"352_CR23","doi-asserted-by":"publisher","unstructured":"Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. The Cochrane database of systematic reviews. 2018;6:Cd001190. https:\/\/doi.org\/10.1002\/14651858.CD001190.pub3.","DOI":"10.1002\/14651858.CD001190.pub3"},{"key":"352_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/978-3-642-23274-9_14","volume":"208","author":"KS Buels","year":"2012","unstructured":"Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;208:317\u201341. https:\/\/doi.org\/10.1007\/978-3-642-23274-9_14.","journal-title":"Handb Exp Pharmacol"},{"key":"352_CR25","doi-asserted-by":"publisher","unstructured":"Castro JMdA, Resende RR, Mirotti L, Florsheim E, Albuquerque LL, Lino-dos-Santos-Franco A et al. Role of M2 muscarinic receptor in the airway response to methacholine of mice selected for minimal or maximal acute inflammatory response. BioMed Res Int. 2013;2013:805627. https:\/\/doi.org\/10.1155\/2013\/805627.","DOI":"10.1155\/2013\/805627"},{"issue":"9","key":"352_CR26","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.celrep.2018.07.082","volume":"24","author":"Y Niwa","year":"2018","unstructured":"Niwa Y, Kanda GN, Yamada RG, Shi S, Sunagawa GA, Ukai-Tadenuma M, et al. Muscarinic acetylcholine receptors Chrm1 and Chrm3 are essential for REM sleep. Cell Rep. 2018;24(9):2231-47.e7. https:\/\/doi.org\/10.1016\/j.celrep.2018.07.082.","journal-title":"Cell Rep"},{"issue":"2","key":"352_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/WNF.0b013e3181c71be9","volume":"33","author":"T Ota","year":"2010","unstructured":"Ota T, Shinotoh H, Fukushi K, Kikuchi T, Sato K, Tanaka N, et al. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol. 2010;33(2):74\u20138. https:\/\/doi.org\/10.1097\/WNF.0b013e3181c71be9.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"352_CR28","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/sj.npp.1300759","volume":"30","author":"T Shiraishi","year":"2005","unstructured":"Shiraishi T, Kikuchi T, Fukushi K, Shinotoh H, Nagatsuka S, Tanaka N, et al. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology. 2005;30(12):2154\u201361. https:\/\/doi.org\/10.1038\/sj.npp.1300759.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"352_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s12640-016-9672-y","volume":"31","author":"M Valis","year":"2017","unstructured":"Valis M, Masopust J, Vysata O, Hort J, Dolezal R, Tomek J, et al. Concentration of donepezil in the cerebrospinal fluid of AD patients: evaluation of dosage sufficiency in standard treatment strategy. Neurotox Res. 2017;31(1):162\u20138. https:\/\/doi.org\/10.1007\/s12640-016-9672-y.","journal-title":"Neurotox Res"},{"key":"352_CR30","doi-asserted-by":"publisher","unstructured":"Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Archives of internal medicine. 1998;158(9):1021\u201331. https:\/\/doi.org\/10.1001\/archinte.158.9.1021.","DOI":"10.1001\/archinte.158.9.1021"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-021-00352-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-021-00352-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T09:55:19Z","timestamp":1630403719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-021-00352-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["352"],"URL":"https:\/\/doi.org\/10.1007\/s40268-021-00352-5","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"28 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Heptares Therapeutics Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jan Liptrot, Steve Dickinson\u00a0and Tim Tasker\u00a0are currently paid employees of Sosei Heptares and have owned stock in the company. David M. Cross is a paid independent consultant for Sosei Heptares.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the medical ethics review board of the foundation Beoordeling Ethiek Biomedisch Onderzoek (BEBO, Assen, The Netherlands).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided informed consent before participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analysed during the current study are filed in EudraCT and are not publicly available (in accordance with the regulations for phase I data). Further information is available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code that is used to model the data is available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}